Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD mice

We previously demonstrated that immunotherapy with dendritic cells (DC) prevented diabetes development in prediabetic NOD mice and that this effect was optimal when using a stimulatory DC population generated from bone marrow cells cultured with granulocyte‐macrophage colony‐stimulating factor (GM‐C...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of immunology 2002-07, Vol.32 (7), p.2021-2030
Hauptverfasser: Feili‐Hariri, Maryam, Falkner, Dewayne H., Morel, Penelope A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We previously demonstrated that immunotherapy with dendritic cells (DC) prevented diabetes development in prediabetic NOD mice and that this effect was optimal when using a stimulatory DC population generated from bone marrow cells cultured with granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and IL‐4. In this study, we have investigated the mechanism by which GM‐CSF‐ and IL‐4‐cultured DC prevent diabetes in prediabetic NOD mice. Histological analysis of pancreatic tissue from DC‐treated mice revealed a reduction in the severity of insulitis compared to controls. Analysisof the T cell response in DC‐treated mice suggested a general shift towards a Th2‐dominated response, as determined by cytokine production following either concanavalin A or anti‐TCR stimulation. Furthermore, sorted CD45RBlo CD25+ CD4+ T cells from the spleen of DC‐treated mice produced high amounts of Th2 cytokines following anti‐TCR stimulation, suggesting that these cells are responsible for the apparent Th2 shift. We conclude that DC therapy may have corrected the immunoregulatory defect in the NOD mouse, thus restoring a balance between pathogenic Th1 cells and protective Th2 cells.
ISSN:0014-2980
1521-4141
DOI:10.1002/1521-4141(200207)32:7<2021::AID-IMMU2021>3.0.CO;2-J